Study of OJP-001 for adult T-cell leukemia/lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called OJP-001 for people with adult T-cell leukemia/lymphoma (ATL) that has come back or not responded to other treatments. The goal is to see if this drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with adult T-cell leukemia/lymphoma and have a positive test for HTLV-1 antibodies
- You must be between 20 and 85 years old
- Your disease must have returned or not responded after at least one prior treatment, including mogamulizumab or chemotherapy
- You must have evidence of the disease in your blood
- You must be able to perform daily activities with minimal help (ECOG 0-2)
- Your liver function must be within certain limits, and you must be expected to live more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding lenalidomide to a standard chemotherapy regimen (EPOCH) helps people with adult T-cell leukemia-lymphoma (ATLL). It aims to improve how well the treatment works.
This trial tests whether a drug called mogamulizumab can prevent adult T-cell leukemia/lymphoma in people who carry the HTLV-1 virus and have a high viral load. It is for patients who have not yet developed the blood cancer.
This trial tests a combination of five drugs for people newly diagnosed with a rare type of lymphoma called angioimmunoblastic T-cell lymphoma (AITL). The goal is to see if this treatment helps control the cancer.
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
This trial tests a new drug called ELVN-001 for people with chronic myeloid leukemia (CML) who have not responded to or could not take at least two prior treatments. It's for Japanese patients, including those with a specific genetic change (T315I mutation). The goal is to see if ELVN-001 can help control the leukemia.
This trial tests a new drug, ONO-4685, for people with certain types of T cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has not responded to standard treatments or cannot tolerate them. The goal is to see if the drug is safe and tolerable.
Hear when a new Adult T-Cell Leukemia/Lymphoma (ATLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.